)
Investor Relations14 Oct 2025
Boost Your Earnings Season Strategy With Real‑Time Alerts
Quartr Pro provides real time alerts, trend analysis and live coverage, giving analysts and investors instant insights to act faster in earnings.
Artelo Biosciences (ARTL) investor relations material
Artelo Biosciences Q2 2025 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q2 2025 earnings summary13 Aug, 2025
Executive summary
Clinical-stage biopharma focused on lipid-signaling therapeutics, with no revenue to date and continued operating losses; net loss of $5.6M for the six months ended June 30, 2025.
Pipeline includes ART27.13 (cancer-related anorexia, Phase 2a), ART26.12 (FABP5 inhibitor, Phase 1), and ART12.11 (CBD cocrystal); ART26.12 completed Phase 1 SAD study, MAD study planned for Q4 2025.
ART12.11 preclinical data showed efficacy in depression and cognitive function; first-in-human study planned for H1 2026.
Adopted a Digital Asset Treasury (DAT) strategy, allocating significant capital to Solana (SOL) cryptocurrency as a non-core treasury reserve asset.
Financial highlights
Net loss of $3.2M for Q2 2025, up from $2.4M in Q2 2024; net loss of $5.6M for the six months ended June 30, 2025.
Operating expenses for Q2 2025 were $3.2M, up from $2.5M year-over-year, driven by higher R&D and professional fees.
R&D expenses were $1.9M and G&A expenses $1.3M for Q2 2025, both increased year-over-year.
Cash and cash equivalents were $2.1M as of June 30, 2025, down from $2.3M at year-end 2024.
Working capital deficit of $3.5M as of June 30, 2025, compared to positive $0.8M at December 31, 2024.
Outlook and guidance
Substantial doubt exists about the ability to continue as a going concern within one year without additional funding.
Ongoing pursuit of equity or debt financing and licensing opportunities; no assurance of success.
R&D and G&A expenses expected to remain at or above current levels as clinical programs advance.
Multiple clinical data announcements anticipated in Q3 2025, including initial data from Phase 2 CARES study (ART27.13).
ART26.12 advancing to MAD study in Q4 2025; ART12.11 first-in-human trial expected in H1 2026.
Elaborate on the digital asset treasury strategy.
When is the ART27.13 Phase 2 data readout expected?
Discuss ART26.12's therapeutic potential in OA.
Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.
Next Artelo Biosciences earnings date
Q3 202511 Nov, 2025
Next Artelo Biosciences earnings date
Q3 202511 Nov, 2025
The essential earnings season companion
The #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
Related articles
)
Edge3 Oct 2025
Epiroc: A Culture of Moving Mountains
From automation to electrification, Swedish industrial giant Epiroc is leading a transformation in how the world mines.
)
Company Research22 Sep 2025
Moody's: Shaping Global Credit
Explore Moody's evolution from publishing manuals to becoming a giant in credit ratings, guiding issuers, investors, and regulators worldwide.
Frequently asked questions
Artelo Biosciences Inc. is a clinical-stage biopharmaceutical company focused on the development and commercialization of proprietary therapeutics. These therapeutics are designed to modulate lipid-signaling pathways, including the endocannabinoid system, aiming to address significant unmet medical needs across various diseases and conditions such as anorexia, cancer, anxiety, pain, neuropathy, and inflammation. Artelo is advancing a diverse portfolio of product candidates, including ART27.13, a synthetic dual cannabinoid G protein-coupled receptor agonist for treating anorexia associated with cancer; ART12.11, a synthetic cannabidiol cocrystal targeting inflammatory bowel disease and post-traumatic stress disorder (PTSD); and ART26.12, a fatty acid binding protein 5 inhibitor intended for breast and prostate cancer, neuropathic and nociceptive pain, and anxiety disorders, including PTSD. The company is headquartered in Solana Beach, California, and its shares are listed on the Nasdaq.
Quartr provides global coverage of all investor relation material from public companies.
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Yes, the Quartr mobile app is free on both iOS and Android.
Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.
Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.
Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.
Explore our global coverage